PMID- 12712472
OWN - NLM
STAT- MEDLINE
DCOM- 20030520
LR  - 20181130
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 97
IP  - 9
DP  - 2003 May 1
TI  - Characterization of antigen processing machinery and Survivin expression in 
      tonsillar squamous cell carcinoma.
PG  - 2203-11
AB  - BACKGROUND: There is a statistically significant association between human 
      leukocyte antigen (HLA) Class I antigen expression and improved prognosis for 
      some patients. This association reflects the control of tumor growth by HLA Class 
      I antigen-restricted, tumor-associated antigen-specific cytolytic T cells. 
      However, progression of other malignant diseases is not associated with the loss 
      of HLA expression. These observations show that the poor prognosis of a subset of 
      tumors, despite high HLA Class I antigen expression, may reflect the development 
      of alternative mechanisms utilized by tumor cells to escape from immune 
      recognition and destruction. METHODS: The authors evaluated the possible 
      correlation between the expression of the antiapoptosis gene, Survivin, HLA Class 
      I, and progression of tonsillar squamous cell carcinomas (TSCC) lesions. Tissue 
      microarrays were constructed from primary TSCC, metastatically involved lymph 
      nodes, adjacent normal mucosa, and tonsillar parenchyma excised for nonmalignant 
      conditions. RESULTS: Immunoperoxidase staining of tissue sections demonstrated 
      that Survivin expression is significantly higher (P < 0.001) in malignant tumors 
      than in normal tissue samples. In addition, Survivin expression is significantly 
      higher (P = 0.05) in metastatic than in primary lesions. Survivin expression in 
      primary lesions correlated positively with delta (P = 0.025), tapasin (P = 
      0.028), and HLA Class I antigen (P = 0.006) expression. The expression patterns 
      of delta, tapasin, HLA Class I antigen, beta-2-microglobulin, and Survivin did 
      not demonstrate any significant association with the clinical course of disease. 
      CONCLUSIONS: For TSCC that maintain the expression of HLA Class I antigen, 
      overexpression of Survivin may provide an alternative explanation for tumor 
      progression.
CI  - Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11311
FAU - Weinman, Eric C
AU  - Weinman EC
AD  - Department of Otorhinolaryngology, Mayo Clinic, Rochester, Minnesota 55906, USA.
FAU - Roche, Patrick C
AU  - Roche PC
FAU - Kasperbauer, Jan L
AU  - Kasperbauer JL
FAU - Cha, Steve S
AU  - Cha SS
FAU - Sargent, Dan J
AU  - Sargent DJ
FAU - Cheville, John
AU  - Cheville J
FAU - Murphy, Linda M
AU  - Murphy LM
FAU - Chen, Lieping
AU  - Chen L
FAU - Wettstein, Peter J
AU  - Wettstein PJ
FAU - Gostout, Bobbie
AU  - Gostout B
FAU - Ferrone, Soldano
AU  - Ferrone S
FAU - Strome, Scott E
AU  - Strome SE
LA  - eng
GR  - CA 85721/CA/NCI NIH HHS/United States
GR  - CA67108/CA/NCI NIH HHS/United States
GR  - CA79915/CA/NCI NIH HHS/United States
GR  - DE00459/DE/NIDCR NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Antiporters)
RN  - 0 (BIRC5 protein, human)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (Immunoglobulins)
RN  - 0 (Inhibitor of Apoptosis Proteins)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Membrane Proteins)
RN  - 0 (Membrane Transport Proteins)
RN  - 0 (Microtubule-Associated Proteins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Survivin)
RN  - 0 (beta 2-Microglobulin)
RN  - 0 (delta protein)
RN  - 0 (tapasin)
SB  - IM
MH  - Antigen Presentation/physiology
MH  - Antiporters/metabolism
MH  - Carcinoma, Squamous Cell/*metabolism/pathology/therapy
MH  - Case-Control Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Expression Regulation, Neoplastic
MH  - Histocompatibility Antigens Class I/*metabolism
MH  - Homeodomain Proteins/metabolism
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Immunoglobulins/metabolism
MH  - Inhibitor of Apoptosis Proteins
MH  - Intracellular Signaling Peptides and Proteins
MH  - Male
MH  - Membrane Proteins/metabolism
MH  - Membrane Transport Proteins
MH  - Microtubule-Associated Proteins/*metabolism
MH  - Middle Aged
MH  - Neoplasm Proteins
MH  - Neoplasm Staging
MH  - Survivin
MH  - Tonsillar Neoplasms/*metabolism/pathology/therapy
MH  - beta 2-Microglobulin/metabolism
EDAT- 2003/04/25 05:00
MHDA- 2003/05/21 05:00
CRDT- 2003/04/25 05:00
PHST- 2003/04/25 05:00 [pubmed]
PHST- 2003/05/21 05:00 [medline]
PHST- 2003/04/25 05:00 [entrez]
AID - 10.1002/cncr.11311 [doi]
PST - ppublish
SO  - Cancer. 2003 May 1;97(9):2203-11. doi: 10.1002/cncr.11311.